Moreover, inspired by Sipuleucel-T therapy for prostate cancer, Munoz et al. developed a vaccine platform consisting of autologous DCs pulsed with tumor membrane vesicles (TMVs) encapsulating personalized tumor antigens, which showed anti-tumor effects in HER2-positive breast cancer and triple-negative breast cancer (Munoz et al., 2021). This evidence concerns the gene ERBB2 and prostate cancer.